logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Order CRaFT 2025
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
    • From Model to Market (MORSE x CCX Workshop)
  • LINKS
  • CONTACT US
logo-top-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Careers
  • SERVICES
    • Our Services
      • Comprehensive Market Access Launch Strategy
      • Market Access Landscape Analysis
      • HTA Planning and Reimbursement Evidence Strategy
      • Negotiation & Stakeholder Engagement Strategy
      • Portfolio & Life Cycle Strategy
      • Expert-Led Training & Customized Workshops
  • REPORTS
    • NEW – Order CRaFT 2025
    • DRD Market Access Trends & Insights
    • Oncology Market Access Trends & Insights
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
    • From Model to Market (MORSE x CCX Workshop)
  • LINKS
  • CONTACT US

CADTH & INESSS Pilot Project: Joint Engagement with Clinical Specialists

September 14, 2018
-
Market Access News
-
Posted by MORSE Team - < 1 min read.

On September 13th, 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) issued details on a new CADTH and Institut national d’excellence en santé et en services sociaux (INESSS) pilot project to jointly engage with clinical specialists.

According to CADTH’s communication, the objectives of the pilot project are to:

  • Strengthen the current pharmaceutical review processes used by CADTH and INESSS with respect to engagement with Canadian clinical specialists.
  • Facilitate a broader representation of clinical specialists, with the goal of integrating pan Canadian expertise into the review processes for drugs that are likely to be associated with complex evaluations and challenging deliberations.
  • Promote efficiency within Canadian health technology assessment processes by reducing duplication of effort.

CADTH and INESSS will collaborate to establish a group of clinical specialists to consult with about select drug products. This consultation will occur in parallel with the respective review process that each organization performs, which will remain independent. The goal of having joint clinical panels is to integrate pan-Canadian expertise into the review process for drugs with challenging deliberations and complex evaluations.

This initial pilot project will be limited to drugs undergoing review through CADTH’s Common Drug Review and INESSS, and will not involve drugs reviewed via CADTH’s pCODR (pan-Canadian Oncology Drug Review) process. CADTH and INESSS will collaborate to select drugs for inclusion in the pilot, and then the drug manufacturers will be notified of the selection. CADTH states that no established review timelines will be affected by being included in this pilot.

Further information on the scope, selection of drugs, clinical panel details, and evaluation of the pilot can be found here: https://cadth.ca/sites/default/files/corporate/CADTH-INESSS-Pilot_Announcement.pdf

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

Share
Tags
CADTH
HTA
INESSS
← PREVIOUS POST
pCPA Monthly Trends & Insights – August 31, 2018
NEXT POST →
pCPA Monthly Trends & Insights – July 31, 2018

Contact Us

MORSE Consulting Inc.

Toronto | Ottawa, Canada

+1-647-717-3179 (Toronto)

+1-613-864-8645 (Ottawa)

info@morseconsulting.ca

NEW A one-day interactive training and scenario-based modelling experience!
A one-day interactive training and scenario-based modelling experience!
Order 2025 Report

2025 Canadian Reimbursement and Forecasting Timelines Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
Social
Connect & Follow:
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
CADTH & INESSS Pilot Project: Joint Engagement with Clinical Specialists
Learn More
Learn More